Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind multiple-ascending-dose Ib/IIa trial of BGT-002 in NASH
CTR20230344Phase 2Completed
- Sponsor
- Burgeon Therapeutics
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BGT-002 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Burgeon Therapeutics. Started Feb 2023; status: completed.
02
Drugs
BGT-002
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20230344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230344.